(Albany, US) DelveInsight launched its new report on Myasthenia Gravis – Market Insights, Epidemiology, and Market Forecast-2030
DelveInsight’s “Myasthenia Gravis – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Myasthenia Gravis, historical and forecasted epidemiology as well as the Myasthenia Gravis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
View report: https://www.delveinsight.com/sample-request/myasthenia-gravis-market
The key facts of the report:
1. Among the European countries, Spain had the highest Myasthenia Gravis prevalence with around 15,275 cases, followed by Germany with about 12,400 cases in 2016. 2. Japan had the lowest prevalent population of Myasthenia Gravis in 2016, with 14,985 cases.
Key benefits of the report: 1. Myasthenia Gravis market report covers a descriptive overview and comprehensive insight of the Myasthenia Gravis epidemiology and Myasthenia Gravis market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.) 2. Myasthenia Gravis market report provides insights on the current and emerging therapies. 3. Myasthenia Gravis market report provides a global historical and forecasted market covering drug outreach in 7 MM. 4. Myasthenia Gravis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Myasthenia Gravis market.
Request for a free sample report: https://www.delveinsight.com/sample-request/myasthenia-gravis-market
The key players in Myasthenia Gravis market are:
1. UCB Pharma 2. Novartis 3. Argenx 4. Ra Pharmaceuticals and many others.
The launch of the emerging therapies is expected to significantly impact Myasthenia Gravis treatment scenario in the upcoming years:- Drugs covered 1. Rozanolixizumab 2. CFZ533 3. Efgartigimod 4. RA101495 And many others
Table of contents: 1. Key Insights 2. Myasthenia Gravis Market Overview at a Glance 3. Myasthenia Gravis Disease Overview 4. Myasthenia Gravis Epidemiology and Patient Population 5. Country Wise Myasthenia Gravis Epidemiology 5.1. United States 5.2. Germany 5.3. France 5.4. Italy 5.5. Spain 5.6. United Kingdom 5.7. Japan 6. Myasthenia Gravis Current Treatment Practices 7. Unmet Needs 8. Myasthenia Gravis Marketed drugs 8.1. Key cross competition- Marketed drugs 8.2. Mestinon: Valeant Pharmaceuticals 8.3. Soliris: Alexion Pharmaceuticals 8.4. Prograf: Astellas Pharma 8.5. Venoglobulin IH: Mitsubishi Tanabe Pharma 9. Myasthenia Gravis Emerging Therapies 9.1. Key cross competition- Emerging Therapies 9.2. Rozanolixizumab: UCB Pharma 9.3. CFZ533: Novartis 9.4. Efgartigimod : Argenx 9.5. RA101495: Ra Pharmaceuticals 9.6. Firdapse: Catalyst Pharmaceuticals 9.7. Hizentra: CSL Behring 9.8. IGIV-C: Grifols Therapeutics 10. Myasthenia Gravis 7 Major Market Analysis 11. Market Outlook by Country 11.1. The United States: Market Outlook 11.2. United States Market Size 11.3. EU-5 Countries: Market Outlook 11.4. Germany 11.5. France 11.6. Italy 11.7. Spain 11.8. United Kingdom 11.9. Japan: Market Outlook 12. Market Drivers 13. Market Barriers 14. Appendix 15. DelveInsight Capabilities 16. Disclaimer 17. About DelveInsight
Related reports:
Myasthenia Gravis – Epidemiology Forecast to 2030
Myasthenia Gravis – Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/